Sections View Full Chapter Figures Tables Videos Annotate Full Chapter Figures Tables Videos Supplementary Content ++ All dosages are for adults unless otherwise specified. For details on pediatric dosages, please refer to Chapter 167. ++ Abciximab (ReoPro): see table on antiplatelet agentsAcetazolamide (Diamox): see table on diuretics(Aldactone) Spironolactone: see table on diureticsAlfentanil (Alfenta): see table on opioidsAminocaproic acid (Amicar): see table on antifibrinolytics(Anectine) Succinylcholine: see table on neuromuscular blocking agents ++Table Graphic Jump Location|Download (.pdf)|PrintAnticholinergicsTachycardiaBronchodilationSedationAntisialagogueAtropine++++++++Scopolamine+++++++Glycopyrrolate (Robinul) (does not cross BBB)++++0+++ ++ See following table. ++Table Graphic Jump Location|Download (.pdf)|PrintAnticoagulants and ReversalDrugArgatrobanDirect thrombin inhibitor2 μg/kg/min infusion up to 10 μg/kg/min (HIT), 350 μg/kg IV over 2–5 min with 25 μg/kg/min infusion (PCI in patients with HIT)Antithrombin III (ATIII, Thrombate III)Binds coagulation factors, preventing formation of clotDetermine preinfusion (baseline) antithrombin III concentration and calculate initial (loading) dosage using following formula:Administer dose to increase antithrombin III concentration to a suggested level of 120% of normal using formulaEnoxaparin (Lovenox)Accelerates activity of antithrombin III30–40 mg SC bid (DVT prophylaxis), 1 mg/kg SC q12 h or 1.5 mg/kg SC q day (Tx of DVT), 1.5 mg/kg/dose SC q12 h (ACS)ProtamineCombines with heparin (strong acid) to form a stable complex (salt)1 mg protamine per mg of active heparinWarfarin (Coumadin)Inhibits factors 2, 7, 9, 10 and proteins C and S5 mg PO, and then maintenance of 2–10 mg PO for goal INR of 2–3++Table Graphic Jump Location|Download (.pdf)|PrintAntiemeticsDrugDose (IV)MechanismAnesthetic considerationsOndansetron (Zofran)4 mg (adults), 0.1 mg/kg (pediatrics) up to 4 mg5-HT3 receptor antagonistProlongs QT intervalHepatic clearanceGranisetron (Kytril)1 mg (adults), 10 μg/kg (pediatrics)5-HT3 receptor antagonistDolasetron (Anzemet)12.5 mg (adults), 0.35 mg/kg5-HT3 receptor antagonistDroperidol (Inapsine)1–2 μg/kg (adults), 0.1 mg/kg (pediatrics)DA antagonist, blocks release of NE, 5-HT, GABAProlongs QT interval (black box warning), hypotension, extrapyramidal effects, avoid in pheochromocytoma, avoid in patients receiving L-dopa therapyDexamethasone (Decadron)4–12 mgAntiemetic mechanism unclearAdminister with caution in patients with DMUseful if airway trauma during repeated intubationsUseful as antiemetic (4 mg)Metoclopramide (Reglan)0.25 mg/kgDA antagonist centrally, peripheral cholinomimeticAvoid in patients with pheochromocytomaCan cause extrapyramidal side effects, neuroleptic malignant syndromeDoes not affect gastric pHPromethazine (Phenergan)12.5–25 mgH1 receptor antagonistDA blockerPartial alpha-blockerRespiratory depressionCNS depressionRare neuroleptic malignant syndrome++Table Graphic Jump Location|Download (.pdf)|PrintAntifibrinolyticsDrugDosageMechanism of actionAminocaproic acid (Amicar)Acute bleeding: 4–5 g during the first hour, followed by 1 g/h for 8 h or until bleeding controlled (maximum daily dose: 30 g)Thrombocytopenia: 0.1 g/kg over 30–60 minBlocks activation of plasminogen to plasminAprotinin (Trasylol)2 million KIU (280 ... Your Access profile is currently affiliated with [InstitutionA] and is in the process of switching affiliations to [InstitutionB]. Please select how you would like to proceed. Keep the current affiliation with [InstitutionA] and continue with the Access profile sign in process Switch affiliation to [InstitutionB] and continue with the Access profile sign in process Get Free Access Through Your Institution Learn how to see if your library subscribes to McGraw Hill Medical products. Subscribe: Institutional or Individual Sign In Error: Incorrect UserName or Password Username Error: Please enter User Name Password Error: Please enter Password Sign in Forgot Password? Forgot Username? Download the Access App: iOS | Android Sign in via OpenAthens Sign in via Shibboleth You already have access! Please proceed to your institution's subscription. Create a free profile for additional features.